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Abstract: The rapid mutations of viruses such as SARS-CoV-2 require vaccine updates and the
development of novel antiviral drugs. This article presents an improved database filtering technology
for a more effective design of novel antiviral agents. Different from the previous approach, where
the most probable parameters were obtained stepwise from the antimicrobial peptide database, we
found it possible to accelerate the design process by deriving multiple parameters in a single step
during the peptide amino acid analysis. The resulting peptide DFTavP1 displays the ability to inhibit
Ebola virus. A deviation from the most probable peptide parameters reduces antiviral activity. The
designed peptides appear to block viral entry. In addition, the amino acid signature provides a clue
to peptide engineering to gain cell selectivity. Like human cathelicidin LL-37, our engineered peptide
DDIP1 inhibits both Ebola and SARS-CoV-2 viruses. These peptides, with broad antiviral activity,
may selectively disrupt viral envelopes and offer the lasting efficacy required to treat various RNA
viruses, including their emerging mutants.
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1. Introduction
Emerging viral infections can cause harm to our society. This was made crystal clear
in the previous Spanish flu and the current severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) pandemic. According to the World Health Organization, COVID-19 has
caused 464 million infections and 6.06 million cumulative deaths globally as of March 21,
2022 [1]. SARS-CoV-2 has also added a burden to our economic, educational, and health
care systems around the world. Similarly, Ebola viruses have a major impact on our society,
causing a significant number of mortalities. Ebola viruses are highly lethal and have an
average mortality rate of 50% [2,3]. Fortunately, vaccines have proven to be effective to
protect humans from SARS-CoV-2 and Ebola virus (EBOV) infections [4–6]. However,
viruses mutate rapidly and have evolved into numerous mutants that could compromise
vaccine protection and cause breakthrough coronavirus infections [7]. Hence, there is a
need to develop alternatives such as antiviral drugs to better manage viral infections.
Antimicrobial peptides (AMPs) are an important factor of the innate immune defense
for both invertebrates and vertebrates, including humans [8–14]. Recently, human defensins
have been shown to inhibit SARS-CoV-2 infection [15]. Likewise, human cathelicidin
LL-37, another key AMP, also demonstrated antiviral activity against SARS-CoV-2 [16].
These antiviral peptides can work through different mechanisms, ranging from immune
regulation to direct inactivation via membrane disruption [17–20]. Hence, natural AMPs
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may be engineered into new therapeutics to help control these viruses [11,12,21–23]. As a
proof of concept, we previously demonstrated that LL-37 could be engineered to inhibit
Ebola virus entry [24].
As an alternative approach, we found it useful to discover novel antimicrobials based
on the antimicrobial peptide database (APD) [25]. This was made possible due to our
systematic classification of AMPs based on the sequence length, net charge, hydrophobic
ratio, post-translational modification, structure, activity, and source organism. In the APD,
most of the AMPs had a peptide length of less than 60 amino acids. The net charge of a
peptide was calculated at pH 7 and chemical modification was considered. The majority of
the peptides in the APD have a net charge in the range of +1 to +7. The hydrophobic amino
acids were defined based on the Kyte–Doolittle hydrophobic scale [26], where residues
of leucine (L), isoleucine (I), valine (V), alanine (A), methionine (M), cysteine (C), and
phenylalanine (F) are hydrophobic. In addition, the APD included tryptophan (W) in
the hydrophobic group. The hydrophobic ratio of a peptide was calculated based on the
sum of all the hydrophobic amino acids mentioned above divided by the peptide length.
The dominant hydrophobic ratios for AMPs are located between 20 and 70%. Peptide
structures are separated into four classes based on the presence or absence of the α-helix
and β-sheet (i.e., α, β, αβ, and non-αβ). In the current APD, 478 peptides are found to have
an α-helical structure based on nuclear magnetic resonance (NMR) spectroscopy and/or
circular dichroism (CD). Only 88 peptides are determined to have a β-sheet structure,
while 116 entries are known to adopt an αβ fold. Finally, the structures of 22 peptides
are found to belong to the non-αβ class (i.e., no α-helix nor β-sheet). Both the peptide
sequence and post-translational modification play an important role in determining 3D
structure and biological activity (e.g., antibacterial, antiviral, antiparasitic, antifungal, and
anticancer) [27].
This study reports the design of novel antiviral peptides by developing an improved
version of the database filtering technology [28], making peptide design more efficient.
Following up on our initial observation of Ebola virus entry inhibition, we validate the
utility of the database filtering approach in designing new antiviral peptides using an Ebola
virus pseudo-type system. In addition, we also evaluate the antiviral effects of DDIP1, a
database-designed inhibitory peptide 1 [27], using both Ebola virus and SARS-CoV-2.
2. Results and Discussion
2.1. Peptide Design via an Improved Database Filtering Technology
The APD, originally established in 2003, was expanded and described in 2009 and
2016 [25,27]. To learn the wisdom of nature, the APD currently focuses on natural peptides
with determined antimicrobial activity, known amino acid sequences, and less than 100
amino acids, leading to a widely used core data set. Our careful annotation of peptide activity data (e.g., antibacterial, antiviral, antifungal, antiparasitic, spermicidal, and anticancer)
laid a solid foundation for designing peptides with the desired activity. In addition, peptide
properties, such as the length, net charge, hydrophobicity, and structure, can be searched
for in a systematic manner. Each parameter can be arrayed to identify the optimum. These
database features enabled the development of database technology for peptide design. The
database filtering technology (DFT) is one such approach that designs new peptides based
on the most probable parameters within a set of peptides with common activity [28]. The
DFT is an ab initio approach to designing peptides because, unlike de novo approaches, it
makes no prior assumptions. The first proposed version of the DFT designed a peptide
with activity against methicillin-resistant Staphylococcus aureus (MRSA), but did not inhibit
Gram-negative bacteria. To design antiviral peptides, the first database filter selected
all 190 antiviral peptides in the database (Summer 2021) as templates. These peptides
were analyzed to determine the AMP length with the highest abundance. The search was
conducted in 10 amino acid increments. The 21–30 residue range had the highest peptide
count (Figure 1). This range would be the most probable length for our peptide design.
Considering the cost of making longer peptides, however, we selected a peptide length
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of 20, which was closest to the lower optimal boundary. We then derived the rest of the
peptide parameters based on the antiviral peptides with 11–20 amino acids. To study the
impact of the AMP length on antiviral activity, we also designed two shorter peptides
with 12 and 16 amino acids. In the original DFT design method, a series of filtering steps
were involved in deriving numerous parameters. For example, three separate filters were
used to determine the frequency of amino acids, net charge, and the hydrophobicity of the
anti-MRSA peptide. Here, we found it possible to derive these three parameters in one step
by analyzing the amino acid frequency plot for the 11–20-peptide length group. In this plot
(Figure 2A), the 20 standard amino acids were separated into four groups based on their
common features: (1) hydrophobic (I, V, L, F, C, M, A, and W), (2) special glycine/proline
(G and P), (3) polar and hydrophilic (T, S, Y, Q, and N), and (4) charged (E, D, H, K, and
R) [25]. We then selected the most abundant amino acid in each group as a representative.
In this manner, 20 amino acids were reduced to four for our peptide design (solid columns
in Figure 2A, top panel). In this plot, the four representative amino acids were leucine
(L), glycine (G), serine (S), and arginine (R). Interestingly, we were not alone in utilizing
this reductionist approach, since nature also uses a small set of amino acids to design
peptides such as θ-defensins. While the hydrophobic group contained I, V, F, L, and C,
the other three groups consisted of a single amino acid (glycine, threonine, and arginine,
respectively) (Figure 2B) [29]. This plot indicated that other amino acids in the special
GP, polar, and charged groups were not preferred in the known θ-defensins. Next, in our
improved design, the amino acid percentages within each amino acid group were summed
(Figure 2A bottom panel) to represent the percentage for each of the four selected amino
acids (L, G, S, or R) in the designed peptides. To design a 20-mer peptide, we calculated
the numbers of the four amino acids L, G, S, and R for this peptide by multiplying the
percentage for each amino acid with the targeted peptide length. Thus, this procedure
enabled us to determine the types and contents of the four representative amino acids
(including hydrophobic and cationic) in one step, increasing the efficiency of this ab initio
method. Next, the most probable structure of the peptide was determined to be α-helical,
because this structure had the highest occurrence in the 11–20 residue range (Figure 3).
This allowed us to place charged and hydrophobic amino acids in a classic amphipathic
pattern, where every two leucines were dispersed with two hydrophilic amino acids. To
determine the potential combinations of these amino acids in the sequence, a statistical
analysis was performed on the possible sequence motifs (four amino acids) that could be
formed. The motifs with the highest abundance in the database were selected to connect the
leucine pairs. The amino acid sequence of the first peptide (DFTavP1) designed to inhibit
viral replication is given in Table 1. For antiviral assays, we utilized a pseudotyped Ebola
virus as described previously [24]. In this study, the designed peptides displayed different
degrees of inhibitory effects on pseudo-EBOV VSV-eGP (vesicular stomatitis virus-Ebola
glycoprotein) infection. DFTavP1, the 20mer, showed an 18% higher inhibition than LL-37
at 2.5 µM (Figure 4). Also, the inhibition increased as the peptide dosage increased.

Figure 1. Antiviral peptide count in the antimicrobial peptide database at various peptide length
ranges [25]. Peptides in the range of 21–30 amino acids were dominant. This length range would be
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the most probable length based on our previous design idea [28]. To reduce peptide cost, we selected
a peptide length of 20 in this study and two even shorter peptides were also designed based on the
peptide parameters with 11–20 amino acids.

Figure 2. A single-step amino acid analysis of antiviral peptides with 11–20 amino acids to derive
multiple most probable parameters for peptide design. (A) Four frequent amino acids (L, G, S, and R,
solid column) were identified from the four groups of amino acids. The percentages of amino acids
for each group were then merged into L, G, S, and R. (B) The amino acid analysis of 19 θ-defensins
registered in the APD. It is remarkable that in nature, θ-defensins are designed in a similar way by
mainly using C, G, T, and R dotted with a few other hydrophobic amino acids.

Figure 3. Count of antiviral peptides with different structures. Data were obtained from the antimicrobial peptide database [25] for antiviral peptides with 11–20 amino acids. Antiviral peptides
with an α-helical structure were dominant with 13 counts. In addition, there were eight antiviral
peptides in the selected length group with β-sheet structures. No antiviral peptides in this length
group had a determined αβ structure (packed or unpacked). Only one antiviral peptide in this
group had a non-αβ structure. In addition, six antiviral peptides in this group were disulfide-linked
(S-S), although their 3D structures are unknown. Note that a similar plot was obtained for antiviral
peptides with 21–30 amino acids (not shown). Therefore, α-helical structure was decided as the most
probable structure for this design.
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Table 1. Database-designed antiviral peptides and their properties.
Peptide

Amino Acid Sequence a

DFTavP1
DFTavP2
DFTavP3
DFTavP4
DDIP1 d

RWLRGLLSGLLRRLLSGLLL
RWLRGLLSGLLRRLLS
RWLRGLLSGLLR
RWVRGVVSGVVRRVVS
GLRCRLGRLLRRLGRCLLR

Length

Net Charge

Pho b

Boman Index c

GRAVY

20
16
12
16
19

+5
+5
+4
+5
+7

55
50
50
50
47

0.6
1.73
1.61
2.12
3.4

0.815
0.331
0.25
0.506
−0.0579

a

All the peptides were C-terminally amidated except for DDIP1. A tryptophan was introduced into the DFT peptides
to facilitate peptide quantification (see Methods section). b Hydrophobic content. c Boman index (originally called
protein binding potential in kcal/mol) [8] was renamed by the APD in 2003 [25]. d All were D-amino acids. In
addition, a disulfide bond exists between the two cysteines C4 and C16 of DDIP1.

Figure 4. Designed AMPs inhibited the infection of pseudo-EBOV virion in Vero cells. (A) AMPs
inhibited pseudo-EBOV (VSV-eGP) infection in Vero cells. Vero cells were pretreated with individual
AMPs at 10 µM for 2 h before VSV-eGP viruses were added. After 24 h of culture, Vero cells were
harvested for flow cytometry analysis to measure viral infection. Percentages of GFP-positive cells
represent percentages of cells infected with VSV-eGP. (B) DFTavP1 and its derivatives inhibited pseudoEBOV (VSV-eGP) infection in Vero cells in a dose-dependent manner. Since AMPs usually inhibit
microbes at micromolar, Vero cells were pretreated with individual AMPs (at 2.5, 5, or 10 µM) for 2 h
before VSV-eGP viruses were added. After 24 h of culture, Vero cells were harvested for flow cytometry
analysis to measure viral infection. (C) DFTavP1, DDIP1, and LL37 inhibited pseudo-EBOV (VSV-eGP)
infection in Vero cells in a dose-dependent manner. Vero cells were pretreated with individual AMPs
(at 2.5, 5, or 10 µM) for 2 h before VSV-eGP viruses were added. After 24 h of culture, Vero cells were
harvested for flow cytometry analysis to measure viral infection.

2.2. Validation of the Most Probable Parameters
Next, we validated the improved methodology by designing additional peptides with
parameters deviated from the optima. A 16 mer (DFTavP2) was designed in the same
manner as DFTavP1 (sequence in Table 1). This peptide length decrease caused a 33%
decrease in the viral inhibition of DFTavP2 at 5 µM compared to DFTavP1. A further
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deviation from the most probable length led to DFTavP3 (a 12 mer in Table 1), which did
not inhibit the VSV–eGP (Figure 4B). Hence, the peptide close to the most probable peptide
length range was more potent than the sequence-shortened counterparts.
To further validate the most probable amino acids, leucine in DFTavP2 was converted
to valine, leading to DFTavP4 (sequence in Table 1). The flow cytometry results suggested
that DFTavP4 entirely lost the ability to inhibit the Ebola pseudo-virus (Figure 4B). This
observation indicated the significance of the most probable hydrophobic leucine in conferring antiviral activity to the peptide. The reason for this might be twofold. First, leucine is
more hydrophobic than valine, enabling a better binding to viruses. Second, leucine has a
higher potential than valine in forming the helical structure required for target binding [25].
To fully validate this, leucine may be converted to other hydrophobic amino acids (I, F, A,
M, C, and W) as well. A previous study revealed the peptide became less soluble when
substituted by isoleucine [28]. Thus, we did not make the same change. As alanine is even
less hydrophobic than valine, we predicted that alanine substitution would also lead to an
inactive peptide. We did not test methionine, since this residue is not favorable for peptide
design due to its readiness of being oxidized. While phenylalanine and tryptophan substitutions may be of interest for future studies, we included one, W, here for UV quantification.
In a different design below, two leucines were transformed to cysteines.
Additional proof of the most probable principle in peptide design came from our
previous database-guided design. The GLK-19 peptide (a 19-residue peptide containing G,
L, and K) designed based on the frequently occurring amino acids from amphibian peptides [25] became active to human immunodeficiency virus type 1 (HIV-1) when all lysines
were replaced with arginines. These changes were determined based on the arginine/lysine
ratios in antibacterial, antifungal, antiviral, and anticancer peptides in the APD, where only
in the antiviral peptides was the arginine/lysine ratio greater than one [30]. Since cysteine
is also abundant in the hydrophobic group of the antiviral peptide amino acid signature
(e.g., see Figure 2A), we changed two leucines in GLR-19 to two cysteines at positions 4
and 16. These changes led to DDIP1 with a disulfide bond. For this study, we created a
new version of DDIP1, where all L-amino acids were converted to D-amino acids to gain
stability to proteases. Our previous study suggested the importance of peptide stability for
inhibiting Ebola viruses [24]. In the inhibition experiment, DDIP1 displayed 7% inhibition
at 2.5 µM and 14% inhibition at 5 µM against the virus. Human LL-37, a known antiviral
peptide [16,24,30], showed a higher viral inhibition than DDIP1 (Figure 4C).
2.3. Antiviral Efficacy of Peptides Treated before or after Viral Infection
We then compared the treatment efficacy of DDIP1 and DFTavP1 postinfection. Human
LL-37 was included as a positive control. At 0, 2, and 4 h postinfection, a dose-responsive
viral inhibition was observed for all the peptides, indicating the effect results from the
peptide treatment (Figure 5A). When treated immediately after infection (delay 0 h), DDIP1,
DFTavP1, and LL-37 displayed ~15%, 69%, and 9% inhibitions at 2.5 µM, respectively.
Hence, DDIP1 and DFTavP1 demonstrated a higher inhibition than LL-37. DFTavP1, in
the 4 h postinfection treatment study, showed a major decrease of 54% inhibition at 5 µM.
The inhibition of the Ebola pseudovirus was reduced with a longer delay after infection for
both DDIP1 and DFTavP1, implying an action on viral entry. The decrease in inhibition
was caused by the decrease in viral load in the extracellular fluid because the intracellular
viral load was increasing. Interestingly, the effect of human LL-37 was relatively constant.
More experiments are required to determine the precise mechanism of DFTavP1 or DDIP1.
We also tested the antiviral activity of DDIP1 against SARS-CoV-2. Like LL-37, DDIP1
showed an inhibitory effect on SARS-CoV-2 in a dose-dependent manner (Figure 5B). At
5 µM, LL-37 inhibited 18% of the virus, while DDIP1 suppressed 42%. At 10 µM, DDIP1
(~55% inhibition) was more potent than LL-37 (~27% inhibition) as well. These results
reinforced the antiviral potency of the database-designed antiviral peptides.
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Figure 5. Designed AMPs inhibited EBOV cell entry and SARS-CoV-2 infection. (A) AMPs targeted
pseudo-EBOV (VSV-eGP) at the early stage of infection. Vero cells were treated with individual
AMPs (at 2.5, 5, or 10 µM) at the same time with VSV-eGP (0 h), or at 2 or 4 h after VSV-eGP infection.
Vero cells were harvested for flow cytometry analysis of GFP levels at 24 h post infection. (B) DDIP1
inhibited SARS-CoV-2 infection. Vero cells were pretreated with individual AMPs (at 2.5, 5, or 10 µM)
for 2 h before SARS-CoV-2 viruses were added. After 24 h of culture, Vero cells were harvested for
immunofluorescence staining to access infection activity.

2.4. Different Requirements for Antiviral and Antibacterial Properties
As our antiviral peptides were designed based on the antimicrobial peptide database [25],
one may wonder whether they are active against bacteria. To obtain a more complete picture,
we used two Gram-positive and four Gram-negative bacterial strains and the minimum
inhibitory concentrations (MIC) of the peptides are provided in Table 2. In contrast to the
antiviral case, DFTavP1 was less active against bacteria than the two shortened peptides
DFTavP2 and DFTavP3 (low MIC values). Interestingly, DDIP1 displayed excellent MIC values
against all the tested antibiotic-resistant pathogens (e.g., MRSA, Escherichia coli, Pseudomonas
aeruginosa, and Klebsiella pneumoniae) in the range of 2–8 µM, comparable to the two shorter
DFT peptides (Table 2). These results unveiled different parameter requirements for designing
antibacterial and antiviral peptides. We speculate that such a difference primarily resulted
from the potential differences in pathogenic targets. It is likely that our designed peptides
(e.g., DDIP1) targeted the viral envelope since many AMPs act on bacterial membranes [8–10].
Another in silico study screened antiviral peptides by docking known antiviral peptides to the
major protease (MPro ) of SARS-CoV-2 without experimental validation [31]. Future studies
on both viruses and bacteria could validate such mechanisms of action. Our speculation
was supported by our previous knowledge on human cathelicidin LL-37 peptides (e.g., GF17 and GI-20), which inhibit both bacteria and viruses [32]. However, the peptide lost its
antiviral effects when the helical structure was disrupted by partially incorporating D-amino
acids. In terms of the mechanism, the helical structure of LL-37 peptides was not a must for
targeting bacterial membranes, but essential to inhibit HIV-1 reverse transcriptase [33]. In
the case of Ebola viruses, only the engineered peptides such as 17BIPHE2 were effective at
the endosomal cell entry step by impairing the cathepsin-B-mediated processing of the Ebola
viral glycoprotein [34].
Table 2. Minimum inhibitory concentration (µM) of database-designed antiviral peptides.
Peptide

S. aureus
USA300

Staphylococcus
epidermidis 1457

Escherichia coli
E416-7

Pseudomonas
aeruginosa #2

Klebsiella pneumoniae
E406-17

Acinetobacter
baumannii B28-16

DFTavP1
DFTavP2
DFTavP3
DFTavP4
DDIP1

8–16
4
4
>64
4

8–16
2
8
NA
4–8

16
4
2–4
16
2

32
8
4–8
NA
4

16–32
4
8
NA
4

8
2
4
NA
2–4
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2.5. Cytotoxicity of Antiviral Peptides
For therapeutic use, it is important that the designed peptides had minimal toxic effects
on mammalian cells. To evaluate the cytotoxicity of the new peptides, we utilized several
cell lines. Vero cells are a model cell for viral infection, derived from the kidney epithelia
of the African green monkey. It appeared that Vero cells were highly sensitive to DFTavP1
(TC50 2.4 µM), but became less sensitive to DDIP1 (TC50 13.0 µM in Table 3). Because SARSCoV-2 infects lung cells, we also tested their cytotoxicity to Calu3 cells. Both DFTavP1 and
DDIP1 showed a TC50 in the range of 12–14 µM, comparable to the human host defense
cathelicidin peptide LL-37 (TC50 19.1 µM). These results indicated a direct antiviral effect of
our peptides at a low peptide concentration (e.g., 2.5 µM), where its secondary toxic effect
on host cells might play a role. The toxic effect of the designed peptides depended on cell
types. The 50% hemolytic concentration (HC50 ) for DDIP1 was greater than 160 µM, the
highest concentration we tested (Table 3). However, both DFTavP1 and DFTavP2 were highly
hemolytic, with an HC50 below 12.5 µM, while DFTavP3, the shortest 12-mer peptide, had
an HC50 of 50 µM. Likewise, DDIP1 was poorly hemolytic to murine red blood cells as well
(HC50 > 160 µM), while DFTavP1 was highly hemolytic (Table 3). In the case of skin HaCaT
cells, the HC50 was 25 µM for DFTavP1, but greater than 100 µM for DDIP1. These results
confirmed the toxicity of DFT peptides. However, the engineered peptide DDIP1 was much
more selective and showed cell-dependent toxicity (Table 3).
Table 3. Cytotoxicity comparison of antiviral peptides to different cells.
Peptide

hRBC HC50

DFTavP1
DDIP1

<12.5 µM
>160 µM

a

mRBC HC50
<10 µM
>160 µM

b

HaCaT TC50

c

Vero Cell TC50

Calu3 Cell TC50

2.39
13

11.88
14.25

25 µM
>100 µM

a

hRBC, human red blood cells; b mRBC, BALB/c mouse red blood cells; c TC50 , the peptide concentration that
killed 50% of human keratinocytes.

3. Materials and Methods
3.1. The Antimicrobial Peptide Database
The APD was originally established in 2003. Since then, it has been updated regularly
and expanded substantially [25,27]. For scientific rigor, the APD applied a set of criteria
for peptide registration (natural peptides, known sequences, known activity, and a size
of less than 100 amino acids). Thus, this database currently focuses on natural peptides
from six life kingdoms, including bacteria, archaea, protists, fungi, plants, and animals [25].
After over 18 years, 26 types of peptide activities (e.g., antibacterial, antiviral, antifungal,
antiparasitic, spermicidal, and anticancer) have been annotated. Such a well-annotated
peptide sequence–activity database provides a unique platform for peptide prediction and
design. The APD enables a thorough statistical analysis of natural AMPs through a variety
of search functions and database filters. Such an analysis identifies key parameters for
peptide design [27].
3.2. Database Filtering Technology (DFT) vs. Improved DFT
The rigorous registration of the data in the APD set the stage for us to develop databaseguided approaches for peptide discovery, ranging from database screening to database filtering
technology [27]. The original database filtering technology [28] consisted of multiple database
filters that allowed us to derive a family of peptides with desired biological activity, followed
by deriving key peptide parameters step by step. In the original DFT, the first filter selected
a set of peptides with activity against Gram-positive bacteria, whereas the improved DFT
used here selected a group of peptides annotated with antiviral activity. The second filter
is common and was used to identify the most probable peptide length. This was achieved
by statistically analyzing the peptides in the APD in bins (every 10 s), so that the peptide
length with the highest count was found. Subsequently, the original DFT identified the most
probable amino acid frequency, net charge, and hydrophobic amino acid in three steps. In
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contrast, the improved DFT derived frequency, net charge, and hydrophobic content in one
step. The rest of the steps in identifying the most probable structure and motifs are shared by
both methods and were detailed elsewhere [28].
3.3. Chemicals and Peptides
All the chemicals were purchased from established vendors such as Fisher and Sigma.
Peptides were created by Genemed Synthesis, Inc. (San Antonio, TX, USA). All the peptides
were highly purified and reached over 95% purity based on HPLC. The correct mass of
each peptide was validated by mass spectrometry (Shimadzu MALDI-8020, Kyoto, Japan
or Thermo Fisher Scientific SALDI-TOF-MS, Waltham, MA, USA). The incorporation of
a tryptophan (W) for each peptide at position 2 (in replacement of a leucine in Table 1)
facilitated peptide quantification on a UV spectrometer (Ultraspec 1100 pro, Amersham
Biosciences) at 280 nm.
3.4. SARS-CoV-2 Safety Statement
All experiments involving SARS-CoV-2 were conducted in an approved BSL-3 facility
of the University of Nebraska Medical Center (UNMC) by dedicated trained personnel.
3.5. Antiviral Assays
Peptide activity against Ebola pseudo-virus was tested using established lab protocols
as described [24]. Inhibitory effects on SARS-CoV-2 were tested as below. Live virus
experiments were performed in the BSL3 laboratory at the UNMC (Omaha, NE, USA).
Briefly, Vero cells (~10,000 cells/well) were seeded in a 96-well plate and cultured in
complete medium overnight. In the prevention experiments, cells were pretreated with
compounds for 2 h at 37 ◦ C. Treatments were washed off and cells were infected with SARSCoV-2 WI at a multiplicity of infection (MOI) of 0.1 in complete media. After 24 h, cells were
fixed with 4% buffered paraformaldehyde for 30 min at room temperature. The fixed cells
were washed with phosphate-buffered saline (PBS), permeabilized with 0.1% (v/v) Triton
X-100 solution for 10 min, then blocked with 3% bovine serum albumin–PBS solution. The
cells were incubated with anti-SARS-CoV-2 spike protein rabbit monoclonal antibody (Sino
Biological, Beijing, China) at 1:1000 overnight at 4 ◦ C, followed by incubation with 1:2000
diluted Alexa Fluor 488 conjugated secondary antibody (Jackson ImmunoResearch) for 1 h
at room temperature. Cell nuclei were counterstained using Hoechst 33,342 (Invitrogen,
#H3570), and cytoplasmic membranes were stained with CellMask (Invitrogen, #C10046).
Noninfected cells and untreated virus-infected cells were included as internal controls.
Cells were imaged using a high-content analysis system, Operetta CLS (PerkinElmer Inc.,
Waltham, MA, USA). Percentage inhibition of viral infection was calculated using Harmony
4.9 software (PerkinElmer Inc.).
3.6. Antibacterial Assays
Peptide activity against bacteria was tested using established lab protocols as described previously [28]. In brief, a peptide concentration gradient with two-fold dilution
was created in the 96-well polystyrene microplates at 10 µL per well. From overnight
cultures, six bacteria (Table 2) were grown to the logarithmic phase (i.e., optical density at
600 nm ≈ 0.5), diluted to ~105 CFU/mL, and partitioned into the 96-well microplates at
90 µL per well. The microplates were incubated at 37 ◦ C overnight and read on a ChroMate
4300 Microplate Reader at 600 nm (GMI, Ramsey, MN, USA).
3.7. Cytotoxicity
Peptide toxicity was evaluated by using human red blood cells (hRBCs) and other host
cells. Hemolysis was conducted as described elsewhere [28]. Briefly, hRBCs, obtained from
the UNMC Blood Bank, were washed three times with phosphate-buffered saline (PBS) and
diluted to a 2% solution (v/v). After peptide treatment, incubation at 37 ◦ C for one hour,
and centrifugation at 13,000 rpm, aliquots of the supernatant were carefully transferred to
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a fresh 96-well microplate. The amount of hemoglobin released was measured at 545 nm.
The percent lysis was calculated by assuming 100% release when human blood cells were
treated with 2% Triton X-100, and 0% release when incubated with PBS buffer. The peptide
concentration that caused 50% lysis of hRBCs was defined as HC50 .
Vero cells (ATCC, CCL-81) or Calu-3 (ATCC, HTB-55) cells were seeded into 96-well
tissue culture plates (Greiner Bio-One, Monroe, NC) and treated with different concentrations of peptides for 24/48 h at 37 ◦ C. Cell viability was examined by Vybrant® MTT
Cell Proliferation Assay Kit (Thermo Fisher Scientific, Grand Island, NY) following the
manufacturer’s instructions. Toxicity assays using HaCaT cells were conducted similarly
as described elsewhere [34].
4. Conclusions
It is useful to identify antiviral peptides that can eliminate all kinds of SARS-CoV-2
variants: alpha, beta, delta, omicron, etc. Based on the antimicrobial peptide database [25],
we previously developed a database filtering technology [28], which was recently proved
to be useful for us in the design of anti-MRSA peptides with systemic efficacy in mice [34].
Here, we improved the original stepwise database filtering method by deriving multiple
most probable parameters in a single amino acid composition analysis for designing antiviral peptides, thereby accelerating this peptide design process based on the antimicrobial
peptide database. Our designed peptides were indeed inhibitory to the Ebola pseudo-virus.
In addition, both human cathelicidin LL-37 and DDIP1 could inhibit SARS-CoV-2. The
decrease in or loss of activity of peptides created with deviated most probable parameters further validated the improved method. Our study demonstrated that the designed
peptides were inhibitory to the Ebola pseudo-virus in either prevention or treatment experiments. The reduced antiviral effect of the designed peptides after additional delay
postinfection implied the blockage of viral entry. Our engineered disulfide-containing
peptide DDIP1 with numerous desired properties could be further optimized to remove
toxicity and developed into a novel treatment for viral infections such as COVID-19. This
should require the study of pharmacokinetics and pharmacodynamics of the optimized
peptide in animal models. It is predicted that DDIP1 is effective against a variety of mutated
viral strains, since it may damage viral envelopes to prevent infection in a similar manner
to disrupt bacterial membranes. Our discovery of novel antiviral peptides may be further
accelerated by applying the machine learning/artificial intelligence algorithms [35–43]
that enable the prediction of both the antiviral activity and toxicity of peptides with the
accumulation of experimental data of AMPs.
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